Trial Profile

Continuous Access to Advanced and Metastatic Renal Cell Carcinoma Therapy With Everolimus Post Pazopanib Treatment

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 27 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary) ; Pazopanib (Primary)
Indications Renal cell carcinoma
Focus Therapeutic Use
Acronyms CATChEz
Sponsors Novartis; Novartis Pharmaceuticals

Most Recent Events

10 Feb 2018 Results assessing safety, efficacy and pharmacodynamics presented at the 2018 Genitourinary Cancers Symposium
26 Sep 2017 Status changed from active, no longer recruiting to discontinued.
01 Nov 2016 Planned End Date changed from 1 Feb 2017 to 1 Nov 2016.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com